Sponsors
The bill centralizes and clarifies congressional oversight of health agencies to improve coordination and speed policymaking, but does so at the risk of concentrating influence, causing short-term disruption, and adding administrative costs.
Hospitals, patients (including those with chronic conditions), and the public: oversight of biomedical research, the FDA, CDC, and public-health policy is centralized under a single House Committee on Health, which should speed policymaking and coordination during health emergencies and promote medical innovation.
Federal employees and lawmakers: creating a dedicated Committee on Health focuses legislative attention and expertise on biomedical research, FDA oversight, CDC activities, and public-health policy, which can improve the quality and consistency of health legislation.
Taxpayers and stakeholders in health policy: removing health insurance program jurisdiction from the Education and the Workforce Committee reduces committee overlap and clarifies jurisdiction, which can lower friction and duplication in drafting health-related laws.
Patients and hospitals: concentrating FDA and CDC oversight in a single committee could reduce cross-committee perspectives and checks, increasing the risk that complex health-policy issues receive narrower or more politicized scrutiny.
Hospitals, patients, and stakeholders: redistributing jurisdiction and realigning staff/expertise during the transition could slow legislative action on health matters in the short term, delaying policy or funding decisions.
Taxpayers: creating a new standing committee will increase congressional staff and administrative costs, producing additional federal expenditures.
Based on analysis of 2 sections of legislative text.
Creates a new House Committee on Health and reallocates oversight of biomedical research, public health, and general‑revenue health care among House committees.
Introduced January 3, 2025 by Warren Davidson · Last progress January 3, 2025
Creates a new standing House Committee on Health and redraws which House committees oversee biomedical research, public health, and health care paid from general revenues. The new committee will take primary jurisdiction over the FDA, CDC-related public health and quarantine, biomedical R&D, and non‑veterans’ health facilities and care funded from general revenues. The rule change also narrows the Committee on Education and the Workforce by removing general jurisdiction over "health insurance programs" and trims several subparagraphs from the Committee on Energy and Commerce’s jurisdiction, shifting oversight responsibilities among House committees. The change is an internal House rules amendment and does not itself create or fund programs.